BR112015004349A2 - peptídeos de ube2t e vacinas contendo os mesmos - Google Patents
peptídeos de ube2t e vacinas contendo os mesmosInfo
- Publication number
- BR112015004349A2 BR112015004349A2 BR112015004349A BR112015004349A BR112015004349A2 BR 112015004349 A2 BR112015004349 A2 BR 112015004349A2 BR 112015004349 A BR112015004349 A BR 112015004349A BR 112015004349 A BR112015004349 A BR 112015004349A BR 112015004349 A2 BR112015004349 A2 BR 112015004349A2
- Authority
- BR
- Brazil
- Prior art keywords
- peptides
- ube2t
- methods
- present
- ctls
- Prior art date
Links
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 9
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 9
- 101150071951 ube2t gene Proteins 0.000 title abstract 5
- 229960005486 vaccine Drugs 0.000 title abstract 2
- 238000000034 method Methods 0.000 abstract 4
- 206010028980 Neoplasm Diseases 0.000 abstract 3
- 210000000612 antigen-presenting cell Anatomy 0.000 abstract 2
- 230000006698 induction Effects 0.000 abstract 2
- 230000001939 inductive effect Effects 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 102000040430 polynucleotide Human genes 0.000 abstract 2
- 108091033319 polynucleotide Proteins 0.000 abstract 2
- 239000002157 polynucleotide Substances 0.000 abstract 2
- 230000002265 prevention Effects 0.000 abstract 2
- 239000004480 active ingredient Substances 0.000 abstract 1
- 230000005809 anti-tumor immunity Effects 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 229940023041 peptide vaccine Drugs 0.000 abstract 1
- 229920001184 polypeptide Polymers 0.000 abstract 1
- 230000002980 postoperative effect Effects 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001154—Enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
- C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/93—Ligases (6)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y603/00—Ligases forming carbon-nitrogen bonds (6.3)
- C12Y603/02—Acid—amino-acid ligases (peptide synthases)(6.3.2)
- C12Y603/02019—Ubiquitin-protein ligase (6.3.2.19), i.e. ubiquitin-conjugating enzyme
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
- C12N2501/515—CD3, T-cell receptor complex
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/70—Enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
- C12N2502/1114—T cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Engineering & Computer Science (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Mycology (AREA)
- Developmental Biology & Embryology (AREA)
- Virology (AREA)
- Urology & Nephrology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
Abstract
resumo patente de invenção: "peptídeos de ube2t e vacinas contendo os mesmos". a presente invenção refere-se a vacinas de peptídeo contra câncer. em particular, peptídeos de epítopo derivados de ube2t que elicitam ctls são providos. células apresentando antígeno isoladas com capacidade de indução de ctl e ctls que se direcionam a tais peptídeos, bem como métodos para indução da célula apresentando antígeno, ou ctl são também providas. a presente invenção provê ainda composições farmacêuticas contendo tais peptídeos de epítopo derivados de ube2t ou polinucleotídeos codificando os polipeptídeos como ingredientes ativos. ainda, a presente invenção provê métodos para o tratamento e/ou profilaxia de (isto é, prevenção) de cânceres (tumores) e/ou a prevenção de uma recorrência pós-operatória do mesmo, bem como métodos para indução de ctls, métodos para indução de imunidade antitumor, usando os peptídeos de epítopo derivados de ube2t, polinucleotídeos codificando os peptídeos ou células apresentando antígeno apresentando os peptídeos ou as composições farmacêuticas da presente invenção.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261699550P | 2012-09-11 | 2012-09-11 | |
| US61/699,550 | 2012-09-11 | ||
| PCT/JP2013/005321 WO2014041784A1 (en) | 2012-09-11 | 2013-09-09 | Ube2t peptides and vaccines containing the same |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| BR112015004349A2 true BR112015004349A2 (pt) | 2017-08-08 |
| BR112015004349B1 BR112015004349B1 (pt) | 2022-11-01 |
Family
ID=50277926
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112015004349-6A BR112015004349B1 (pt) | 2012-09-11 | 2013-09-09 | Composição e método in vitro para indução de um ctl, composição farmacêutica para o tratamento de câncer, método in vitro para indução de uma apc com capacidade de indução de ctl, bem como uso e método para avaliação de um peptídeo que apresenta uma habilidade para induzir um ctl |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US10092634B2 (pt) |
| EP (1) | EP2895600B1 (pt) |
| JP (1) | JP6283861B2 (pt) |
| KR (1) | KR102110873B1 (pt) |
| CN (2) | CN107881158B (pt) |
| AU (1) | AU2013317194B2 (pt) |
| BR (1) | BR112015004349B1 (pt) |
| CA (1) | CA2873155C (pt) |
| DK (1) | DK2895600T3 (pt) |
| ES (1) | ES2784862T3 (pt) |
| HK (1) | HK1212730A1 (pt) |
| IL (1) | IL236690B (pt) |
| MX (1) | MX362912B (pt) |
| PL (1) | PL2895600T3 (pt) |
| RU (1) | RU2663350C2 (pt) |
| SG (2) | SG10201701866QA (pt) |
| TW (1) | TWI632162B (pt) |
| WO (1) | WO2014041784A1 (pt) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6715004B2 (ja) | 2015-12-25 | 2020-07-01 | 宏 半田 | 免疫賦活化剤およびその製造方法 |
| SI3573600T1 (sl) | 2017-01-25 | 2022-07-29 | Ose Immunotherapeutics | Postopek za proizvodnjo obstojne emulzije za dostavo peptida |
| CN111787930A (zh) * | 2017-10-06 | 2020-10-16 | 芝加哥大学 | 针对癌症特异性抗原对t淋巴细胞的筛选 |
| KR102322832B1 (ko) * | 2019-04-22 | 2021-11-12 | 한국과학기술연구원 | 인간 백혈구 항원 a24:02 대립유전자에 특이적으로 결합하는 펩타이드 및 이의 용도 |
| CN113679829B (zh) | 2020-05-18 | 2024-01-02 | 北京繁易纳维科技有限公司 | 一种预防癌症术后复发的肿瘤疫苗及其制备方法和应用 |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4722848A (en) | 1982-12-08 | 1988-02-02 | Health Research, Incorporated | Method for immunizing animals with synthetically modified vaccinia virus |
| US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
| US5804566A (en) | 1993-08-26 | 1998-09-08 | The Regents Of The University Of California | Methods and devices for immunizing a host through administration of naked polynucleotides with encode allergenic peptides |
| US5679647A (en) | 1993-08-26 | 1997-10-21 | The Regents Of The University Of California | Methods and devices for immunizing a host against tumor-associated antigens through administration of naked polynucleotides which encode tumor-associated antigenic peptides |
| US5739118A (en) | 1994-04-01 | 1998-04-14 | Apollon, Inc. | Compositions and methods for delivery of genetic material |
| US5736524A (en) | 1994-11-14 | 1998-04-07 | Merck & Co.,. Inc. | Polynucleotide tuberculosis vaccine |
| US5922687A (en) | 1995-05-04 | 1999-07-13 | Board Of Trustees Of The Leland Stanford Junior University | Intracellular delivery of nucleic acids using pressure |
| WO1998004720A1 (en) | 1996-07-26 | 1998-02-05 | Sloan-Kettering Institute For Cancer Research | Method and reagents for genetic immunization |
| US7041297B1 (en) | 1998-06-25 | 2006-05-09 | Sumitomo Pharmaceuticals Company | Tumor antigen peptides originating in cyclophilin B |
| KR20010083111A (ko) | 1998-07-14 | 2001-08-31 | 길리스 스티브 | 전립선암의 치료 및 진단을 위한 조성물 및 방법 |
| NZ511055A (en) | 1998-10-05 | 2003-10-31 | Pharmexa As | Novel methods for therapeutic vaccination |
| US6468546B1 (en) | 1998-12-17 | 2002-10-22 | Corixa Corporation | Compositions and methods for therapy and diagnosis of ovarian cancer |
| AU2002227498A1 (en) * | 2000-07-31 | 2002-02-13 | Kyogo Itoh | Tumor antigen |
| TW200512298A (en) | 2003-09-24 | 2005-04-01 | Oncotherapy Science Inc | Method of diagnosing breast cancer |
| US20070202109A1 (en) | 2003-09-24 | 2007-08-30 | Oncotherapy Science, Inc. | Method Of Diagnosing Breast Cancer |
| WO2008102906A1 (en) | 2007-02-20 | 2008-08-28 | Oncotherapy Science, Inc. | Hspc-hrpc transition genes |
| TWI610939B (zh) | 2007-02-21 | 2018-01-11 | 腫瘤療法 科學股份有限公司 | 表現腫瘤相關抗原之癌症的胜肽疫苗 |
| TW200908998A (en) * | 2007-06-27 | 2009-03-01 | Oncotherapy Science Inc | Compositions and methods of treating cancer |
| WO2010032696A1 (ja) | 2008-09-18 | 2010-03-25 | 学校法人慶應義塾 | がんの診断方法と治療方法 |
| TWI500932B (zh) | 2008-12-05 | 2015-09-21 | Oncotherapy Science Inc | Ｗｄｒｐｕｈ抗原決定位胜肽以及含此胜肽之疫苗 |
| BRPI0923402A2 (pt) | 2008-12-24 | 2015-08-04 | Oncotherapy Science Inc | Peptídeos c10rf59 e vacinas incluindo os mesmos. |
| TW201102081A (en) | 2009-05-11 | 2011-01-16 | Oncotherapy Science Inc | TTK peptides and vaccines including the same |
| TW201216982A (en) * | 2010-10-21 | 2012-05-01 | Oncotherapy Science Inc | WDHD1 peptides and vaccines including the same |
| CA2815100A1 (en) * | 2010-10-21 | 2012-04-26 | Oncotherapy Science, Inc. | C18orf54 peptides and vaccines including the same |
| AU2011336019B2 (en) * | 2010-12-02 | 2016-07-07 | Oncotherapy Science, Inc. | TOMM34 peptides and vaccines including the same |
-
2013
- 2013-09-09 DK DK13837757.7T patent/DK2895600T3/da active
- 2013-09-09 JP JP2015530559A patent/JP6283861B2/ja active Active
- 2013-09-09 SG SG10201701866QA patent/SG10201701866QA/en unknown
- 2013-09-09 CN CN201711214045.9A patent/CN107881158B/zh active Active
- 2013-09-09 AU AU2013317194A patent/AU2013317194B2/en active Active
- 2013-09-09 BR BR112015004349-6A patent/BR112015004349B1/pt active IP Right Grant
- 2013-09-09 CA CA2873155A patent/CA2873155C/en active Active
- 2013-09-09 ES ES13837757T patent/ES2784862T3/es active Active
- 2013-09-09 PL PL13837757T patent/PL2895600T3/pl unknown
- 2013-09-09 SG SG11201501761SA patent/SG11201501761SA/en unknown
- 2013-09-09 US US14/400,169 patent/US10092634B2/en active Active
- 2013-09-09 CN CN201380047407.3A patent/CN104619833B/zh active Active
- 2013-09-09 EP EP13837757.7A patent/EP2895600B1/en active Active
- 2013-09-09 MX MX2015003017A patent/MX362912B/es active IP Right Grant
- 2013-09-09 KR KR1020147031506A patent/KR102110873B1/ko active IP Right Grant
- 2013-09-09 RU RU2015113436A patent/RU2663350C2/ru active
- 2013-09-09 WO PCT/JP2013/005321 patent/WO2014041784A1/en active Application Filing
- 2013-09-10 TW TW102132531A patent/TWI632162B/zh active
-
2015
- 2015-01-13 IL IL236690A patent/IL236690B/en active IP Right Grant
-
2016
- 2016-01-19 HK HK16100536.3A patent/HK1212730A1/zh unknown
-
2018
- 2018-08-31 US US16/120,102 patent/US11266729B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12015502638A1 (en) | Novel immunotherapy against several tumors, such as lung cancer, including nsclc | |
| BR112017007093A2 (pt) | composições e métodos de uso para aumento da resposta imune e terapia do câncer | |
| PH12021551208A1 (en) | Novel immunotherapy against several tumors, such as lung cancer, including nsclc | |
| UA113729C2 (xx) | Мутантний поліпептид інтерлейкіну-2 (il-2) | |
| BR112016009402A2 (pt) | Peptídeo, linfócitos t citotóxicos (ltc) ativados, método para sua produção, anticorpo, receptor de células t, ácido nucleico, célula hospedeira, uso dos mesmos, kit, método para produzir uma vacina anticâncer personalizada para um paciente individual | |
| BR112012023621A2 (pt) | composição dos peptídeos associados a tumor e vacina anticâncer relacionada para o tratamento do câncer gástrico e outros cânceres | |
| BR112015021828A2 (pt) | Peptídeos de kntc2 e vacinas que contêm os mesmos | |
| MX2010014044A (es) | Peptidos de epitope cdca1 y vacunas que contienen los mismos. | |
| BR112015004349A2 (pt) | peptídeos de ube2t e vacinas contendo os mesmos | |
| UA114298C2 (uk) | Пептид торк та вакцина, що його містить | |
| MX2011012013A (es) | Peptidos ttk y vacunas que incluyen los mismos. | |
| MX2022006022A (es) | Peptido derivado de depdc1 y vacuna que lo contiene. | |
| BR112013005448A2 (pt) | peptídeos de ttll4 e vacinas contendo os mesmos. | |
| EP4219525A3 (en) | Foxm1-derived peptide, and vaccine including same | |
| SG10201900933YA (en) | Koc1-derived peptide and vaccine including same | |
| MX2011010191A (es) | Peptidos c6orf167 y vacunas que continen los mismos. | |
| BR112015012234A2 (pt) | Peptídios sema5b e vacinas contendo os mesmos | |
| BR112017002212A2 (pt) | peptídeo derivado de cdca1 e vacina contendo o mesmo | |
| PH12016502008A1 (en) | Novel immunotherapy against several tumors of the blood, such as acute myeloid lukemia (aml) | |
| BR112012014345A2 (pt) | peptídeos tmem22 e vacinas incluindo os mesmos | |
| BR112017002193A2 (pt) | peptídeo derivado de urlc10 e vacina contendo o mesmo | |
| MX2012011666A (es) | Peptidos cluap1 y vacunas que incluyen los mismos. | |
| AR113131A2 (es) | Inmunoterapia contra diversos tumores como el cáncer de pulmón, incluido el carcinoma de pulmón amicrocítico (nsclc) | |
| MY193910A (en) | Novel immunotherapy against several tumors, such as lung cancer, including nsclc | |
| MY194241A (en) | Novel Immunotherapy Against Several Tumors, Such as Lung Cancer, Including NSCLC |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 09/09/2013, OBSERVADAS AS CONDICOES LEGAIS |